TCT Takes The Stage; Sapien Set To Play The Lead
This article was originally published in The Gray Sheet
Executive Summary
U.S. approval of the first transcatheter aortic valve replacement may be at least a year away, but the buzz surrounding the technology could go into overdrive at this week's Transcatheter Cardiovascular Therapeutics conference in Washington, D.C